Novo Nordisk drops single-chamber device for CagriSema, says no change to program
Fierce Biotech reports the device decision does not alter the cagrilintide-semaglutide combination's development plans.
MH
By Maren Holt · Senior Reporter, GLP-1
May 6 03:00 ETSource: Fierce Biotech
The wire
- 01Novo Nordisk has abandoned a single-chamber delivery device for CagriSema, its cagrilintide plus semaglutide combination, according to Fierce Biotech.
- 02Device format affects manufacturing and patient handling for the amylin-incretin combination that Novo is positioning against Lilly's obesity franchise.
- 03Novo says the program is otherwise unchanged; the report does not detail a replacement presentation or timing.
From the source
Read at fiercebiotech.com‘No change’ for CagriSema as Novo ditches single-chamber device